SUTRO BIOPHARMA INC's ticker is STRO and the CUSIP is 869367102. A total of 110 filers reported holding SUTRO BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 1.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,680,816 | -4.1% | 2,501,676 | +28.5% | 0.10% | -16.5% |
| Q2 2023 | $9,051,969 | +71.0% | 1,946,660 | +69.9% | 0.12% | +65.8% |
| Q1 2023 | $5,293,531 | -59.2% | 1,145,786 | -28.6% | 0.07% | -64.0% |
| Q4 2022 | $12,962,170 | +86.1% | 1,604,229 | -36.0% | 0.20% | +157.0% |
| Q3 2022 | $6,966,960 | +84.4% | 2,508,210 | +245.9% | 0.08% | +5.3% |
| Q2 2022 | $3,778,000 | +37.4% | 725,081 | +292.4% | 0.08% | +275.0% |
| Q4 2021 | $2,749,000 | -10.7% | 184,765 | +13.3% | 0.02% | -25.9% |
| Q3 2021 | $3,079,000 | +58.8% | 163,007 | +56.3% | 0.03% | +50.0% |
| Q2 2021 | $1,939,000 | -81.9% | 104,320 | -77.9% | 0.02% | -85.1% |
| Q1 2021 | $10,728,000 | +51.7% | 471,332 | +44.7% | 0.12% | +95.2% |
| Q4 2020 | $7,072,000 | +242.1% | 325,765 | +58.4% | 0.06% | +51.2% |
| Q3 2020 | $2,067,000 | – | 205,698 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,675,579 | $5,814,259 | 1.78% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,883,693 | $20,416,415 | 1.10% |
| Kynam Capital Management, LP | 1,552,675 | $5,387,782 | 0.88% |
| Parkman Healthcare Partners LLC | 1,182,168 | $4,102,123 | 0.75% |
| Rubric Capital Management LP | 3,344,810 | $11,606,491 | 0.44% |
| BVF INC/IL | 3,347,946 | $11,617,373 | 0.31% |
| DAFNA Capital Management LLC | 283,079 | $982,284 | 0.31% |
| SECTORAL ASSET MANAGEMENT INC | 432,339 | $1,500,216 | 0.29% |
| Eversept Partners, LP | 769,638 | $2,670,644 | 0.23% |
| Frazier Life Sciences Management, L.P. | 780,000 | $2,706,600 | 0.18% |